| Dexamethasone studied in …STUDIED_INderived10 of 1,461show all (up to 200) |
|---|
| → studied in | NCT03418038Phase 2 · recruiting Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia · 1,461 trials list this drug (392 active) | — | — | Lymphoma,Hodgkin Lymphoma,Chronic Myelomonocytic Leukemia+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04181827Phase 3 · active not recruiting A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma · 1,461 trials list this drug (392 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04973605Phase 1/Phase 2 · recruiting A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma · 1,461 trials list this drug (392 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05288062Phase 2 · terminated Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma · 1,461 trials list this drug (392 active) | — | — | Multiple Myeloma,Smoldering Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06788912Phase 2 · active not recruiting Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) · 1,461 trials list this drug (392 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06948084Phase 2 · recruiting Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse · 1,461 trials list this drug (392 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01745588Phase 2 · completed Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma · 1,461 trials list this drug (392 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04133636Phase 2 · active not recruiting A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma · 1,461 trials list this drug (392 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04923893Phase 3 · active not recruiting A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy · 1,461 trials list this drug (392 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05083169Phase 3 · active not recruiting A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma · 1,461 trials list this drug (392 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |